| Emerging Vaccine Immunotherapy In NSCLC: The Adverse Reactions of Recent Clinical Trials and Future Directions | | |
| PD-1/PD-L1 inhibitors in treatment-naïve, advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials | | |
| The role of immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-small cell lung cancer: an updated systematic review and meta-analysis of randomized controlled trials | | |
| The Blood Proteome of Imminent Lung Cancer Diagnosis | | |
| Sputum analysis by flow cytometry; an effective platform to analyze the lung environment | | 2022 |
| Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events | | 2022 |
| TRAIL-induces Src mediated MEK/ERK, SMAD3 and β-catenin signalling in apoptosis resistant NSCLC cells | | |
| Emerging Approaches to Complement Low-Dose Computerized Tomography for Lung Cancer Screening: A Narrative Review | | 2022 |
| Evaluation of Lung Cancer Incidence Dynamics in Kyrgyzstan | | 2022 |
| Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial? | | 2022 |
| Management of screen-detected lung nodule: A single-center experience | Formosan Journal of Surgery | 2022 |
| Air pollution and lung cancer survival in Pennsylvania | Lung Cancer | 2022 |
| Role of low dose computed tomography on lung cancer detection and mortality - an updated systematic review and meta-analysis | Monaldi Archives for Chest Disease | |
| Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression | Expert Review of Clinical Immunology | |
| Experimental approach to obtaining subcutaneous xenograft of non-small cell lung cancer | Issledovaniâ I Praktika V Medicine | 2022 |
| Study of biological activity of 2-quinoline-2-yl-derivative 1,3-tropolone in experiment | Issledovaniâ I Praktika V Medicine | 2022 |
| 18F-FDG PET/CT for Response Assessment in Lung Cancer | Seminars in Nuclear Medicine | 2022 |
| De- "bug"-ing the microbiome in lung cancer. | Cancer and Metastasis Reviews | 2022 |
| The state of the art for artificial intelligence in lung digital pathology. | Journal of Pathology | 2022 |
| A five-step strategy for building an LDCT lung cancer screening program | | |
| Experimental investigation of microwave holographic reflectometry for lung tumor detection | Measurement: Journal of the International Measurement Confederation | 2022 |
| Hypothesized Explanations for the Observed Lung Cancer Survival Benefit Among Hispanics/Latinos in the United States. | Journal of Racial and Ethnic Health Disparities | 2022 |
| Heavy Smoking Patients Receiving a Lung Cancer Screen Want to Quit: A Call for Tailored Cessation Interventions | Frontiers in Medicine | 2022 |
| Kliniğimizde İzlenen Akciğer Kanseri Hastalarında Klinik Özellikler ve Sağ Kalımı Etkileyen Faktörlerin Değerlendirilmesi: Zonguldak Bülent Ecevit Üniversitesi Hastanesi Örneği | Medical Journal of Western Black Sea | 2022 |
| GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer. | World Journal of Clinical Oncology | 2022 |
| The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab. | Frontiers in Oncology | 2022 |
| Table_7.docx | | 2018 |
| Table_6.docx | | 2018 |
| Table_5.docx | | 2018 |
| Table_4.docx | | 2018 |
| Table_3.docx | | 2018 |
| Table_2.docx | | 2018 |
| Table_1.DOCX | | 2018 |
| Image_9.pdf | | 2018 |
| Image_8.PDF | | 2018 |
| Image_7.PDF | | 2018 |
| Image_6.PDF | | 2018 |
| Image_5.PDF | | 2018 |
| Image_4.PDF | | 2018 |
| Image_3.PDF | | 2018 |
| Image_2.PDF | | 2018 |
| Image_1.PDF | | 2018 |
| Data_Sheet_1.DOCX | | 2018 |
| Table_1.DOCX | | 2020 |
| Image_4.jpeg | | 2019 |
| Image_3.jpeg | | 2019 |
| Image_2.jpg | | 2019 |
| Image_1.JPEG | | 2019 |
| Inflammatory Respiratory Diseases: Correlation Between Lung Cancer and COVID-19 | | 2022 |
| Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study. | Targeted Oncology | 2021 |
